DIFFICULTIES ANTIVIRAL THERAPY IN PATIENTS WITH HCV-CIRRHOSIS AND CHRONIC KIDNEY DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prior to the AVT chronic HCV-infection a careful assessment of comorbidity, especially renal function, so that's kidneys are involved in the metabolism of the majority of antiviral drugs, and can greatly influence the development of serious adverse events difficult to control, particularly anemia.

Full Text

Restricted Access

About the authors

O. Lukina

Russian Peoples Friendship University

A. Balashova

Russian Peoples Friendship University

Email: nastasya.balashova@yandex.ru

A. Almazova

Hospital № 64, Moscow

Candidate of Medical Sciences

K. Evsigneeva

Hospital № 52, Moscow

Candidate of Medical Sciences

O. Arisheva

Russian Peoples Friendship University; Hospital № 52, Moscow

I. Garmash

Russian Peoples Friendship University

Candidate of Medical Sciences

O. Kotenko

Russian Peoples Friendship University; Hospital № 52, Moscow

Candidate of Medical Sciences

References

  1. Fried M., Shiffman M., Reddy K. et al. Peginterferon alfa-2a plus ribavirin of chronic hepatitis C virus infection // N. Engl. J. Med. - 2002; 347: 975-82.
  2. Пегасис®. Инструкция к медицинскому применению.
  3. EASL. International Consensus Conference on Hepatitis C // J. Hepatol. -2002; (36): 973-7.
  4. Dieterich D., Wasserman R., Bräu N. et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa // Am. J. Gastroenterol. - 2003; 98: 2491-9.
  5. Brennan B., Wang K., Blotner S. et al. Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment // Antimicrob. Agents and Chemother. - 2013; 57 (12): 6097-105.
  6. Wang K., Lawal A., Majchrowitz M. et al. Pharmacokinetics (PK) of ribavirin(RBV) in patients with renal impairment or end-stage disease (ESRD) and chronic hepatitis C during treatment with peginterferon alfa-2a (PEGASYS) and RBV(COPEGUS) // J. Hepatol. - 2008; 48: 1142.
  7. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection // J. Hepatol. - 2013; 60 (2): 392-420.
  8. Ребетол®. Инструкция по медицинскому применению.
  9. Davis G., Wong J., McHutchison J. et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C // Hepatology. - 2003; 38: 645-52.
  10. Ющук Н.Д., Ивашкин В.Т., Жданов К.В. Рекомендации по диагностике и лечению взрослых больных гепатитом С 2013 г. // Рос. журн. гастроэнтерол., гепатол., колопроктол. - 20134 23 (2): 41-70.
  11. Thévenot T., Cadranel J., Di Martino V. et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C // Hepatology. - 2007; 45: 377-83.
  12. Бакулин И.Г., Сандлер Ю.Г. Гематологические нежелательные явления при проведении противовирусной терапии у больных с хроническим гепатитом С // Гепатологический форум. - 2011; 4: 2-14.
  13. Lindahl K., Schvarcz R., Bruchfeld A. et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia // J. Viral. Hepatol. - 2004; 11: 84-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies